Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program.
New full-service offering streamlines and accelerates clinical trial recruitment with patient-centric, scalable prescreening
SEATTLE--(BUSINESS WIRE)-- Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of Tasso Care® for Prescreening, an end-to-end services solution to maximize the success of a prescreening program. The new offering expands the foundation and expertise of the Tasso Care services platform in remote blood collection and analysis to support clinical trial recruitment.
Tasso Care for Prescreening is designed to support the prescreening of trial participants for a number of cardiometabolic and serostatus markers. Additional panels to support immunology, cardiovascular disease, and other therapeutic areas will launch as part of the prescreening platform throughout Q1 of 2024 as validation protocols are completed.
Screening participants is a major bottleneck for drug development, often leading to trial delays and high screen failure rates. Tasso Care revolutionizes the enrollment process by replacing time-consuming, labor-intensive clinic visits with convenient, automated prescreening testing at scale. By providing a virtually painless blood draw experience from home, Tasso drives higher clinical trial engagement rates by simplifying the operational process, optimizing the participants’ blood collection experience, and ensuring a high-quality sample is returned to the lab. Tasso Care enables large populations to be screened simultaneously anytime, anywhere, boosting trial access and diversity.
“Accelerating and expanding access to clinical trials is a key step toward improving healthcare,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Too often, trials experience enrollment delays due to the difficulty of identifying rare populations and obtaining up-to-date data. By making screening scalable and convenient, Tasso Care for Prescreening will empower programs to reach and recruit the right participants faster than ever.”
Tasso Care for Prescreening is intended for use under institutional review board (IRB)-reviewed prescreening protocols. To learn more about Tasso Care for Prescreening, please visit www.tassoinc.com/prescreening.
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208541169/en/
Contacts
Dina Schneider
(206) 822-4186 x1016
media@tassoinc.com
Source: Tasso, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20240208541169/en
